Clinical Trial Update: OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update of Tarceva (OSI-774) in stage III/IV non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: OSI Pharmaceuticals | Conditions: Carcinoma, Non-small-cell Lung | Phase 3 | Status: COMPLETED